Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.36)
# 318
Out of 5,169 analysts
142
Total ratings
53.73%
Success rate
16.26%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $4.63 | +115.98% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $98.97 | +41.46% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $14.05 | +611.74% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $96.55 | +34.65% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $7.16 | +249.16% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $120.80 | +65.56% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $3.10 | +867.74% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $70.94 | +55.06% | 13 | Oct 30, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.59 | +528.93% | 1 | Oct 6, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $68.64 | +9.27% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.71 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $25.17 | -0.68% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $11.19 | +123.41% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $6.06 | -0.99% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $228.06 | +22.77% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $5.33 | +838.09% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $6.32 | +216.46% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $256.33 | -16.12% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.58 | +93.80% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.44 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $8.89 | +237.46% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.61 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.23 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $37.89 | +137.53% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.25 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $143.93 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $57.57 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.39 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.61 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $114.52 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $9.65 | +1,143.52% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $55.20 | +17.75% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $13.36 | -17.66% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $130.71 | -0.54% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $759.05 | +0.13% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $24.04 | -37.60% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $13.44 | +309.23% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.79 | +1,575.98% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.15 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.64 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $443.18 | -43.59% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $94.22 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $72.33 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.92 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $15.62 | +40.85% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.92 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $56.05 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $219.76 | -56.77% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $4.63
Upside: +115.98%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $98.97
Upside: +41.46%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $14.05
Upside: +611.74%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $96.55
Upside: +34.65%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $7.16
Upside: +249.16%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $120.80
Upside: +65.56%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $3.10
Upside: +867.74%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $70.94
Upside: +55.06%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.59
Upside: +528.93%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $68.64
Upside: +9.27%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.71
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $25.17
Upside: -0.68%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $11.19
Upside: +123.41%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $6.06
Upside: -0.99%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $228.06
Upside: +22.77%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $5.33
Upside: +838.09%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $6.32
Upside: +216.46%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $256.33
Upside: -16.12%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.58
Upside: +93.80%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.44
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $8.89
Upside: +237.46%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.61
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.23
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $37.89
Upside: +137.53%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.25
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $143.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $57.57
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.39
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $114.52
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $9.65
Upside: +1,143.52%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $55.20
Upside: +17.75%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $13.36
Upside: -17.66%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $130.71
Upside: -0.54%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $759.05
Upside: +0.13%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $24.04
Upside: -37.60%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $13.44
Upside: +309.23%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.79
Upside: +1,575.98%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.15
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.64
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $443.18
Upside: -43.59%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $94.22
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $72.33
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.92
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $15.62
Upside: +40.85%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $13.92
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $56.05
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $219.76
Upside: -56.77%